✦ LIBER ✦

Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study

✍ Scribed by Clive Holmes; David Wilkinson; Christine Dean; Corinne Clare; Mohammed El-Okl; Christine Hensford; Sheram Moghul

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 58 KB
Volume: 22
Category: Article
ISSN: 0885-6230
DOI: 10.1002/gps.1667

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risperidone for psychosis of Alzheimer's

Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial

✍ Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Cl 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Objective: To evaluate the efficacy and safety of low-dose risperidone in treating psychosis of alzheimer's disease (ad) and mixed dementia (md) in a subset of nursing-home residents who had dementia and aggression and who were participating in a randomized placebo-controlled trial of risperidon

A six-month double-blind, randomized, pl

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule

✍ Bengt Winblad; Jeffrey Cummings; Niels Andreasen; George Grossberg; Marco Onofrj 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB

## Abstract ## Objectives To compare the efficacy, safety and tolerability of a novel rivastigmine transdermal patch with conventional rivastigmine capsules and placebo in patients with Alzheimer's disease (AD). ## Methods In this 24‐week, multicenter, double‐blind, double‐dummy, placebo‐ and ac

A randomised double-blind placebo-contro

A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease

✍ Peter J. Connelly; Neil P. Prentice; Gary Cousland; Jim Bonham 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Abstract ## Objectives (1) to assess the effect of 1 mg folic acid supplementation of cholinesterase inhibitors (ChI) in a 6 month double‐blind placebo‐controlled study of patients with Alzheimer's Disease (AD) and (2) to assess whether outcome measures were affected by changes in homocysteine

Quetiapine treatment for behavioural and

Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study

✍ D. Paleacu; Y. Barak; I. Mirecky; D. Mazeh 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

## Abstract ## Setting Treating elderly patients with Alzheimer's disease (AD) and behavioral and psychological symptoms of dementia (BPSD) is challenging due to the increased risk of iatrogenic movement disorders with old neuroleptics and the seemingly increasing risk of cardiovascular events wit

Lavender oil as a treatment for agitated

Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study

✍ Clive Holmes; Vivienne Hopkins; Christine Hensford; Vanessa MacLaughlin; David W 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 49 KB 👁 1 views

## Abstract ## Objective To determine whether aromatherapy with lavender oil is effective in the treatment of agitated behaviour in patients with severe dementia. ## Design A placebo controlled trial with blinded observer rater. ## Setting A long‐stay psychogeriatric ward. ## Patients Fiftee

Safety and tolerability of once-daily ve

Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease

✍ Roy W. Jones; Antony Bayer; Fraser Inglis; Andrew Barker; Ravinder Phul 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## Abstract ## Objective To assess the safety and tolerability of three different dosing schedules of memantine in patients with moderate to severe Alzheimer's disease (AD). ## Method This 12‐week, randomised, double‐blind study, investigated three dosing schedules of memantine: OD1 (20 mg once